- Trial Phase
- Phase 2 completed; Phase 3 registrational trial expected to begin by end of 2026
- Time to Market
- ~4-6 years (Phase 3 trial ~2-3 years + regulatory review)
- Why 5/10
- ATH434 is Alterity's sole asset and just cleared the End-of-Phase 2 FDA meeting (July 7, 2026). The next hard milestone is Phase 3 pivotal trial initiation targeted by end of 2026 (~6 months out). However, Phase 3 initiation is not a binary efficacy readout; the actual pivotal data readout/PDUFA is years away. ImpactScore 5 reflects a mid-stage drug with an imminent program milestone but no binary approval catalyst in the next 12 months.
ATH434 is the entirety of Alterity's value. The stock surged ~96% on Phase 2 data (Jan 2025) and has held gains through the FDA registrational-pathway confirmation (July 2026). The next catalyst is Phase 3 launch by end of 2026, which derisks the program but does not produce efficacy data. Watch for financing/dilution as the company funds a pivotal trial with A$49M in cash burning ~A$5M/qtr — a capital raise is likely before Phase 3 enrollment completes.
Price Chart
Executive Summary
ATH434 is an oral iron-chaperone drug from Alterity Therapeutics (ATHE) targeting Multiple System Atrophy (MSA), a rare, fatal neurodegenerative disease with NO approved disease-modifying treatments. Phase 2 data showed a 48% slowing of disease progression at the 50mg dose (p=0.02) and was published at AAN 2025. The drug has FDA Fast Track and Orphan Drug designations. In July 2026, the FDA officially confirmed the registrational pathway for a Phase 3 pivotal trial. Competition includes Lundbeck's amlenetug (Phase 3, anti-alpha-synuclein antibody). Alterity has ~A$49M cash (~9 quarters runway at current burn) but will likely need to raise capital to fund the pivotal trial.
How It Works
ATH434 is an oral "iron chaperone" — it grabs excess, toxic iron that builds up in brain cells and redistributes it to where it's harmless. In Multiple System Atrophy (MSA), too much reactive iron causes proteins to clump together and kill neurons. By fixing iron balance, ATH434 aims to slow or stop the disease from getting worse.
Trial Status
Two Phase 2 trials completed with positive results: ATH434-201 (77-patient randomized, double-blind, placebo-controlled in early-stage MSA) and ATH434-202 (open-label in more advanced MSA). FDA End-of-Phase 2 meeting concluded with confirmed registrational pathway (July 2026). Phase 3 pivotal trial on track to start by end of 2026.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 3 pivotal trial (targeted by end of 2026)
- Potential capital raise / financing to fund Phase 3
- Medical conference presentations (May 2026 conferences already announced)
- Any potential expansion into Parkinson's disease or Friedreich's ataxia indications (preclinical/early research)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALTERITY THERAPEUTICS LTD 6-K ATHE ·Originating report